Dr. Smith Discusses CAR T Cells in Multiple Myeloma

Video

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric androgen receptor (CAR) T-cell therapy in multiple myeloma.

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric androgen receptor (CAR) T-cell therapy in multiple myeloma.

The target of CAR T-cell therapy in multiple myeloma seems to be anti—B-cell maturation antigen (BCMA), says Smith. The investigational BCMA CAR T-cell therapy bb2121 had an objective response rate of 78% in patients with relapsed/refractory disease, according to interim findings of a phase I dose-escalation study (NCT02658929).

Smith says that next steps are going to include using a fully human CAR to minimize the potential immune responses against CAR.

Related Videos
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
David Porter, MD
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Alexandra Gomez Arteaga, MD
Paul Harmatz, MD
Mark Walters, MD
Mitchel Horwitz, MD
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
© 2024 MJH Life Sciences

All rights reserved.